Unused medications (UM) are an important issue, with the waste associated with UM a burden to the health-care system. The aims of this study were to clarify the amount and costs of UM in patients with advanced cancer at the time of their last admission to a palliative care unit and to explore the factors contributing to the cost of UM and how patients dealt with UM.
Methods:
A prospective observational study was conducted in single palliative care unit. Unused medications were classified into 6 categories and the number and cost of UM by category calculated per patient. Patients were classified into 2 cost groups (high and low) based on the total cost of UM, and the number and cost of UM by category were compared between these 2 groups.
Results:
Of 194 consecutive hospitalized patients, data were analyzed for 90. The mean number and cost of UM per patient was 440 and US$301, respectively. Opioids accounted for 47% of the cost of UM. Comparing costs by UM category, the proportion of opioids (51% vs 21%; P < .0001) and oral anticancer drugs (14% vs 3%; P = .02) was higher in the high- than in the low-cost group.
Conclusion:
Based on the results of the present study, the estimated annual waste cost of UM for patients with cancer who died in Japan was approximately US$110 million. Interventions to educate patients regarding UM and to eliminate barriers to opioid use may help reduce the cost of UM, particularly opioids and anticancer drugs.
TongAYPeakeBMBraundR. Disposal practices for unused medications around the world. Environ Int. 2011;37(1):292–298.
2.
GlassmeyerSTHincheyEKBoehmeSE. Disposal practices for unwanted residential medications in the United States. Environ Int. 2009;35(3):566–572.
3.
FranklinRLRodgersGB. Unintentional child poisonings treated in United States hospital emergency departments: national estimates of incident cases, population-based poisoning rates, and product involvement. Pediatrics. 2008;122(6):1244–1251.
4.
RuhoyISDaughtonCG. Beyond the medicine cabinet: an analysis of where and why medications accumulate. Environ Int. 2008;34(8):1157–1169.
5.
LewisETCucciareMATraftonJA. What do patients do with unused opioid medications?Clin J Pain. 2014;30(8):654–662.
6.
DartRCSurrattHLCiceroTJ. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372(3):241–248.
7.
SilvestreJReddyAde la CruzM. Frequency of unsafe storage, use, and disposal practices of opioids among cancer patients presenting to the emergency department. Palliat Support Care. 2017;15(6):638–643.
8.
de la CruzMReddyABalankariV. The impact of an educational program on patient practices for safe use, storage, and disposal of opioids at a comprehensive cancer center. Oncologist. 2017;22(1):115–121.
9.
GumminDDMowryJBSpykerDABrooksDEFraserMOBannerW. 2016 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th Annual Report. Clin Toxicol (Phila). 2017;55(10):1072–1252.
10.
BoundJPKitsouKVoulvoulisN. Household disposal of pharmaceuticals and perception of risk to the environment. Environ Toxicol Pharmacol. 2006;21(3):301–307.
11.
BeirensTMvan BeeckEFDekkerRBrugJRaatH. Unsafe storage of poisons in homes with toddlers. Accid Anal Prev. 2006;38(4):772–776.
12.
KhanUBloomRANicellJALaurensonJP. Risks associated with the environmental release of pharmaceuticals on the U.S. Food and Drug Administration “flush list”. Sci Total Environ. 2017;609:1023–1040.
13.
OsterbergLBlaschkeT. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
14.
RuddyKMayerEPartridgeA. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59(1):56–66.
15.
MarinDBazeosAMahonFX. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388.
16.
IbrahimAREliassonLApperleyJF. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733–3736.
17.
MathesTPieperDAntoineSLEikermannM. Adherence influencing factors in patients taking oral anticancer agents: a systematic review. Cancer Epidemiol. 2014;38(3):214–226.
18.
FoulonVSchoffskiPWolterP. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg. 2011;66(2):85–96.
19.
GanesanPSagarTGDubashiB. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol. 2011;86(6):471–474.
20.
McCowanCShearerJDonnanPT. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer. 2008;99(11):1763–1768.
21.
MakubateBDonnanPTDewarJAThompsonAMMcCowanC. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515–1524.
22.
SimpsonSHEurichDTMajumdarSR. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333(7557):15.
23.
MiaskowskiCDoddMJWestC. Lack of adherence with the analgesic regimen: a significant barrier to effective cancer pain management. J Clin Oncol. 2001;19(23):4275–4279.
24.
OldenmengerWHSillevis SmittPAEde RaafPJvan der RijtCCD. Adherence to analgesics in oncology outpatients: focus on taking analgesics on time. Pain Pract. 2017;17(5):616–624.
25.
PartridgeAHAvornJWangPSWinerEP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94(9):652–661.
26.
BannaGLCollovaEGebbiaV. Anticancer oral therapy: emerging related issues. Cancer Treat Rev. 2010;36(8):595–605.
LawAVSakharkarPZargarzadehA. Taking stock of medication wastage: unused medications in US households. Res Social Adm Pharm. 2015;11(4):571–578.
29.
Hill-TaylorBWalshKAStewartSHaydenJByrneSSketrisIS. Effectiveness of the STOPP/START (Screening tool of older persons’ potentially inappropriate prescriptions/screening tool to alert doctors to the right treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016;41(2):158–169.
30.
SpeerNDDiosoJCasnerPR. Costs and implications of discarded medication in hospice. J Palliat Med. 2013;16(8):975–978.
31.
HauserJMChenLPaiceJ. Down the drain: the cost of medications wasted in hospice. J Pain Symptom Manage. 2006;31(5):379–380.
32.
The lists of the price standards for medicines prescribed under the health insurance system and the information on generic drugs. 2016; http://www.mhlw.go.jp/topics/2014/03/tp0305-01.html. Accessed March 14, 2018.
WeissSCEmanuelLLFaircloughDLEmanuelEJ. Understanding the experience of pain in terminally ill patients. Lancet. 2001;357(9265):1311–1315.
36.
MoritaTMiyashitaMShibagakiM. Knowledge and beliefs about end-of-life care and the effects of specialized palliative care: a population-based survey in Japan. J Pain Symptom Manage. 2006;31(4):306–316.
37.
AkiyamaMTakebayashiTMoritaT. Knowledge, beliefs, and concerns about opioids, palliative care, and homecare of advanced cancer patients: a nationwide survey in Japan. Support Care Cancer. 2012;20(5):923–931.
38.
MoritaTTsunodaJInoueSChiharaS. Concerns of Japanese hospice inpatients about morphine therapy as a factor in pain management: a pilot study. J Palliat Care. 2000;16(4):54–58.
39.
BicketMCLongJJPronovostPJAlexanderGCWuCL. Prescription opioid analgesics commonly unused after surgery: a systematic review. JAMA Surg. 2017;152(11):1066–1071.
40.
MaughanBCHershEVShoferFS. Unused opioid analgesics and drug disposal following outpatient dental surgery: a randomized controlled trial. Drug Alcohol Depend. 2016;168:328–334.
41.
BartelsKMayesLMDingmannCBullardKJHopferCJBinswangerIA. Opioid use and storage patterns by patients after hospital discharge following surgery. PLoS One. 2016;11(1):e0147972.
42.
McCauleyJLBackSEBradyKT. Pilot of a brief, web-based educational intervention targeting safe storage and disposal of prescription opioids. Addict Behav. 2013;38(6):2230–2235.
43.
ReddyAde la CruzMRodriguezEM. Patterns of storage, use, and disposal of opioids among cancer outpatients. Oncologist. 2014;19(7):780-785.
